Patents by Inventor Timothy Clackson

Timothy Clackson has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20070292922
    Abstract: Single AAV vector constructs for regulated expression of an immunoglobulin molecule or fragment thereof and methods of making and using the same are described. The AAV vectors comprise a regulated promoter operably linked to the coding sequence for a first and second immunoglobulin coding sequence, a sequence encoding a self-processing cleavage site between the coding sequence for the first and second immunoglobulin coding sequence and a additional proteolytic cleavage site, which provides a means to remove the self processing peptide sequence from an expressed immunoglobulin molecule or fragment thereof. The vector constructs find utility in enhanced production of biologically active immunoglobulins or fragments thereof in vitro and in vivo.
    Type: Application
    Filed: March 28, 2007
    Publication date: December 20, 2007
    Applicants: Cell Genesys, Inc., ARIAD Pharmaceuticals, Inc.
    Inventors: Jianmin Fang, Karin Jooss, Minh Nguyen, Thomas Harding, Timothy Clackson, Victor Rivera
  • Publication number: 20070148774
    Abstract: A member of a specific binding pair (sbp) is identified by expressing DNA encoding a genetically diverse population of such sbp members in recombinant host cells in which the sbp members are displayed in functional form at the surface of a secreted recombinant genetic display package (rgdp) containing DNA encoding the sbp member or a polypeptide component thereof, by virtue of the sbp member or a polypeptide component thereof being expressed as a fusion with a capsid component of the rgdp. The displayed sbps may be selected by affinity with a complementary sbp member, and the DNA recovered from selected rgdps for expression of the selected sbp members. Antibody sbp members may be thus obtained, with the different chains thereof expressed, one fused to the capsid component and the other in free form for association with the fusion partner polypeptide. A phagemid may be used as an expression vector, with said capsid fusion helping to package the phagemid DNA.
    Type: Application
    Filed: November 1, 2006
    Publication date: June 28, 2007
    Applicants: MEDICAL RESEARCH COUNCIL, CAMBRIDGE ANTIBODY TECHNOLOGY LIMITED
    Inventors: John McCafferty, Anthony Pope, Kevin Johnson, Hendricus Mattheus Hoogenboom, Andrew Griffiths, Ronald Jackson, Kasper Holliger, James Marks, Timothy Clackson, David Chiswell, Gregory Winter, Timothy Bonnert
  • Publication number: 20060247265
    Abstract: Disclosed is the use of an mTOR inhibitor for treatment of certain eye disorders.
    Type: Application
    Filed: April 28, 2005
    Publication date: November 2, 2006
    Inventors: Timothy Clackson, Leonard Rozamus
  • Publication number: 20060194829
    Abstract: Disclosed are compositions and methods for treating or preventing mucositis by administering to the patient an FKBP ligand prior to, during, or after treatments commonly associated with the development of mucositis such as certain chemotherapies, radiation therapies, or combinations thereof, but in particular, administration of an mTOR inhibitor such as rapamycin, AP23573, CC1779 or everolimus.
    Type: Application
    Filed: December 20, 2005
    Publication date: August 31, 2006
    Inventors: Timothy Clackson, Camille Bedrosian
  • Patent number: 6566073
    Abstract: Materials and methods involving conditional retention domains (CRDs) are disclosed. Also disclosed are fusion proteins containing CRDs and cells expressing such fusion proteins. In addition, the invention provides novel methods for producing target proteins in vivo using fusion proteins containing conditional retention domains and methods for identifying novel CRDs.
    Type: Grant
    Filed: October 19, 1999
    Date of Patent: May 20, 2003
    Assignee: Ariad Gene Therapeutics, Inc.
    Inventors: Victor Rivera, Timothy Clackson, James Rothman